ALB and chronic kidney disease: The DAPA-CKD trial enrolled 4304 patients with CKD (eGFR 25–75 mL/min/1.73 m2, median ~43 mL/min/1.73 m2) and a urinary albumin-to-creatinine ratio (UACR) of 200 to 5000 mg/g, of whom approximately 67.5% had T2DM.